18 results on '"Sean P. Murphy"'
Search Results
2. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
- Author
-
Charlotte Lee, Zsofia D. Drobni, Amna Zafar, Carlos A. Gongora, Daniel A. Zlotoff, Raza M. Alvi, Jana Taron, Paula K. Rambarat, Sara Schoenfeld, Ramya C. Mosarla, Vineet K. Raghu, Sarah E. Hartmann, Hannah K. Gilman, Sean P. Murphy, Ryan J. Sullivan, Alexander Faje, Udo Hoffmann, Lili Zhang, Thomas Mayrhofer, Kerry L. Reynolds, and Tomas G. Neilan
- Subjects
Oncology ,Cardiology and Cardiovascular Medicine - Published
- 2022
3. Relation of High-Sensitivity Cardiac Troponin I and Obstructive Coronary Artery Disease in Patients Without Acute Myocardial Infarction
- Author
-
Reza Mohebi, Laurel Jackson, Cian P. McCarthy, Gillian Murtagh, Sean P. Murphy, Andrew Abboud, Hannah Miksenas, Hanna K. Gaggin, and James L. Januzzi
- Subjects
Male ,Cholesterol ,Diabetes Mellitus, Type 2 ,Troponin T ,Troponin I ,Myocardial Infarction ,Humans ,Coronary Artery Disease ,Cardiology and Cardiovascular Medicine ,Biomarkers ,Article - Abstract
The relation of high-sensitivity cardiac troponin I (hs-cTnI) concentration and presence of obstructive coronary artery disease (CAD) in patients without myocardial infarction (MI) is unclear. Study participants selected from patients free of MI who underwent coronary angiography with or without intervention were enrolled, and hs-cTnI measured. A gradient boosting model was implemented to build a model for detection of CAD. Cox proportional hazard regression was used to assess the association of hs-cTnI and adverse cardiovascular (CV) outcome. Among 978 study participants, 607 patients (62%) had CAD. Higher concentrations of hs-cTnI were associated with chronic kidney disease, heart failure, CAD, male gender, current tobacco use, anemia, age, and low-density lipoprotein cholesterol. History of CAD, male gender, type 2 diabetes mellitus, hs-cTnI, anemia, age, and high-density lipoprotein cholesterol were the most influential factors for detection of CAD. The gradient boosting model had an area under the curve of 0.82, accuracy of 75%, sensitivity of 88%, specificity of 52%, positive predictive value of 76%, and negative predictive value of 72% for detection of CAD. Increase in 1 log unit of hs-cTnI was significantly associated with increased risk of incident MI (hazard ratio [HR] 1.34, 95% confidence interval [CI] 1.22 to 1.47, p0.001), CV mortality (HR 1. 24, 95% CI 1.11 to 1.39, p0.001), and composite of incident MI or CV mortality (HR 1.29, 95% CI 1.20 to 1.40, p0.001). In conclusion, among patients without acute MI and CAD, higher concentrations of hs-cTnI were associated with the presence of CAD and linked to increased risk of future CV events. ClinicalTrials.gov Identifier: NCT00842868.
- Published
- 2022
4. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan
- Author
-
Peder L. Myhre, Margaret F. Prescott, Sean P. Murphy, James C. Fang, Gary F. Mitchell, Jonathan H. Ward, Brian Claggett, Akshay S. Desai, Scott D. Solomon, and James L. Januzzi
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2022
5. Immune checkpoint inhibitors for cancer and venous thromboembolic events
- Author
-
Sean P. Murphy, Hannah K Gilman, Raza M. Alvi, Zsofia D. Drobni, Rebecca Karp-Leaf, Kerry L. Reynolds, Vineet K. Raghu, Sarah Hartmann, Ryan J. Sullivan, Jingyi Gong, Daniel A. Zlotoff, Matthew J. Frigault, Leyre Zubiri, Hang Lee, Tomas G. Neilan, and Amna Zafar
- Subjects
Cancer Research ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,Immune checkpoint inhibitors ,Deep vein ,Hazard ratio ,Cancer ,Retrospective cohort study ,medicine.disease ,Thrombosis ,Article ,Pulmonary embolism ,medicine.anatomical_structure ,Oncology ,Internal medicine ,medicine ,business - Abstract
BACKGROUND: Immune checkpoint inhibitors (ICI) are widely used cancer treatments. There are limited data the risk for developing venous thromboembolism (VTE) among patients on an ICI. METHODS: This was a retrospective study of 2854 patients who received ICIs at a single academic center. VTE events, defined as a composite of deep vein thrombosis (DVT) or pulmonary embolism (PE), were identified by individual chart review and were blindly adjudicated using standard imaging criteria. A self-controlled risk-interval design was applied with an “at-risk period” defined as the two-year period after, and the “control period”, defined as the two-year prior to treatment. The hazard ratio (HR) was calculated using a fixed-effect proportional hazards model. RESULTS: Of the 2854 patients, 1640 (57.5%) were men; mean age was 64±13 years. The risk for VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI. The rate of VTE was >4-fold higher after starting an ICI (HR 4.98, 95% CI 3.65 – 8.59, p
- Published
- 2021
6. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
- Author
-
Uvette Lou, Lawrence S. Blaszkowsky, Vineet K. Raghu, Sean P. Murphy, John W. Clark, Zsofia D. Drobni, Erica Tavares, Ramya C. Mosarla, Hannah K Gilman, Raza M. Alvi, Maeve Jones-O'Connor, Tomas G. Neilan, Colin D. Weekes, Sarah Hartmann, Amna Zafar, Matthew Lei, and Jeffrey W. Clark
- Subjects
medicine.medical_specialty ,Side effect ,business.industry ,Incidence (epidemiology) ,Cancer ,Vasospasm ,medicine.disease ,Chest pain ,Single Center ,nervous system diseases ,body regions ,Oncology ,Internal medicine ,Coronary vasospasm ,cardiovascular system ,medicine ,Medical history ,cardiovascular diseases ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,circulatory and respiratory physiology - Abstract
Background Coronary vasospasm is a recognized side effect of 5-fluorouracil (5-FU). There are limited and conflicting data on the incidence, risk factors, and prognostic effect of 5-FU–associated vasospasm. Objectives This study sought to assess the incidence, risk factors, and prognostic implications of 5-FU coronary vasospasm among patients receiving 5-FU regimens at a single tertiary care center. Methods The study conducted a retrospective analysis of all patients who received 5-FU at a single academic center from January 2009 to July 2019. Vasospasm was defined as the occurrence of a typical chest pain syndrome in the presence of 5-FU. The presence of associated electrocardiogram changes or elevated biomarkers was used to further confirm the diagnosis. Patients with vasospasm were compared with patients treated with 5-FU without vasospasm in a 1:2 ratio. Data regarding demographics, medical history, and follow-up were collected by manual chart review. Results From approximately 4,019 individual patients who received 5-FU from 2009 to 2019 at a single center, 87 (2.16%) developed vasospasm. Patients who developed vasospasm were younger (age 58 ± 13 years vs. 64 ± 13 years; p = 0.001) and were less likely to have any cardiovascular risk factors (70.1% vs. 84.5%; p = 0.007). Patients with vasospasm and patients without vasospasm were otherwise similar in terms of types of cancer, stage of cancer, sex, and race. There was no significant difference in progression-free survival, overall mortality or cancer specific mortality between patients who developed vasospasm versus those who did not. Conclusions In a large, single-center report of 5-FU–associated vasospasm, patients who developed vasospasm were younger, had lower rates of traditional cardiovascular risk factors, and had no significant difference in progression-free or overall survival compared with those who did not develop vasospasm.
- Published
- 2021
7. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
- Author
-
Ileana L. Piña, Alexander Camacho, Nasrien E. Ibrahim, John C. Burnett, G. Michael Felker, Seethalakshmi R. Iyer, Javed Butler, Alan S. Maisel, Scott D. Solomon, James L. Januzzi, Cheryl A. Abbas, Sean P. Murphy, and Margaret F. Prescott
- Subjects
medicine.medical_specialty ,Tetrazoles ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,Sacubitril ,Angiotensin Receptor Antagonists ,03 medical and health sciences ,0302 clinical medicine ,Atrial natriuretic peptide ,Internal medicine ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Neprilysin ,Heart Failure ,Ejection fraction ,business.industry ,Aminobutyrates ,Biphenyl Compounds ,Stroke Volume ,Middle Aged ,medicine.disease ,Drug Combinations ,Treatment Outcome ,Valsartan ,Heart failure ,cardiovascular system ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Atrial Natriuretic Factor ,Sacubitril, Valsartan ,medicine.drug - Abstract
This study sought to assess associations between longitudinal change in atrial natriuretic peptide (ANP) and reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF).Neprilysin inhibition results in an increase of several vasoactive peptides that may mediate the beneficial effects of sacubitril/valsartan, including ANP.In a prospective study of initiation and titration of sacubitril/valsartan in patients with HFrEF, blood was collected at scheduled time points into tubes containing protease inhibitors. This pre-specified exploratory analysis included patients in whom ANP was measured at baseline and serially through 12 months of treatment.Among 144 participants (mean age: 64.5 years; left ventricular ejection fraction: 30.8%), following initiation of sacubitril/valsartan, there was an early and significant increase in ANP, with the majority of rise from 99 pg/ml at baseline to 156 pg/ml at day 14 (p 0.001). There was a further trend toward a second increase from day 30 to day 45 (p = 0.07). At maximal rise, ANP had doubled. In longitudinal analyses, early rise in ANP was followed by a subsequent increase in urinary cycle guanosine monophosphate. Larger early increase in ANP was associated with larger later improvements in left ventricular ejection fraction and left atrial volume index (p 0.001 for both).Concentrations of ANP doubled after initiation of sacubitril/valsartan in patients with HFrEF. Larger early increases in ANP were associated with a greater magnitude of subsequent reverse cardiac remodeling. (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).
- Published
- 2021
8. INFLAMMATION ACROSS UNIVERSAL DEFINITION OF HEART FAILURE STAGES: RESULTS OF CASABLANCA STUDY
- Author
-
Reza Mohebi, Yuxi Liu, Roland Van Kimmenade, Hanna Kim Gaggin, Sean P. Murphy, and James L. Januzzi
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
9. DEFINING THE PREVALENCE AND CHARACTERISTICS OF CORONARY ARTERY DISEASE AMONG PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION USING CT-FFR (DEFINE TYPE 2 MI)
- Author
-
Cian P. McCarthy, Sean P. Murphy, Hannah Miksenas, Daniel Amponsah, Paula Rambarat, Allison Levin, Avanthi Raghavan, Reza Mohebi, Claire Lin, Campbell D.K. Rogers, Jason H. Wasfy, Ron Blankstein, Brian B. Ghoshhajra, Sandeep Hedgire, and James L. Januzzi
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
10. Proteomics as a Path to More Refined Heart Failure Therapeutics
- Author
-
Sean P. Murphy and James L. Januzzi
- Subjects
Heart Failure ,Proteomics ,medicine.medical_specialty ,business.industry ,Spironolactone ,medicine.disease ,chemistry.chemical_compound ,chemistry ,Heart failure ,Internal medicine ,Path (graph theory) ,Cardiology ,Humans ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Mineralocorticoid Receptor Antagonists - Published
- 2021
11. Inflammation in Heart Failure
- Author
-
Cian P. McCarthy, Rahul Kakkar, James L. Januzzi, and Sean P. Murphy
- Subjects
business.industry ,Inflammation ,State of the art review ,030204 cardiovascular system & hematology ,Systemic inflammation ,Bioinformatics ,medicine.disease ,Inflammatory biomarkers ,Pathogenesis ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Heart failure ,medicine ,In patient ,030212 general & internal medicine ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
It has long been observed that heart failure (HF) is associated with measures of systemic inflammation. In recent years, there have been significant advancements in our understanding of how inflammation contributes to the pathogenesis and progression of HF. However, although numerous studies have validated the association between measures of inflammation and HF severity and prognosis, clinical trials of anti-inflammatory therapies have proven mostly unsuccessful. On this backdrop emerges the yet unmet goal of targeting precise phenotypes within the syndrome of HF; if such precise definitions can be realized, and with better understanding of the roles played by specific inflammatory mediators, the expectation is that targeted anti-inflammatory therapies may improve prognosis in patients whose HF is driven by inflammatory pathobiology. Here, the authors describe mechanistic links between inflammation and HF, discuss traditional and novel inflammatory biomarkers, and summarize the latest evidence from clinical trials of anti-inflammatory therapies.
- Published
- 2020
12. Left Ventricular Thrombus
- Author
-
Cian P. McCarthy, James L. Januzzi, Muthiah Vaduganathan, Ramkumar V. Venkateswaran, Avinainder Singh, Deepak L. Bhatt, Leslie L. Chang, Melvin Joice, Jose Rivero, and Sean P. Murphy
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,030204 cardiovascular system & hematology ,Left ventricular thrombus ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Embolism ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,Myocardial infarction complications ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Myocardial infarction diagnosis ,Thrombus ,Cardiology and Cardiovascular Medicine ,business ,Complication - Abstract
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI). However, with improvements in percutaneous coronary intervention
- Published
- 2019
13. Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction
- Author
-
Sean P. Murphy, Cian P. McCarthy, Joshua Cohen, Muthiah Vaduganathan, James L. Januzzi, Maeve Jones-O'Connor, Jason H. Wasfy, Saad Rehman, Avinainder Singh, and David S. Olshan
- Subjects
medicine.medical_specialty ,Rehabilitation ,Extramural ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Coronary thrombus ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
Although the concept of myocardial infarction (MI) occurring in the absence of coronary thrombus was first identified in 1939, it was 2007 before the term type 2 MI , referring to infarctions related to supply–demand imbalance, was first introduced into clinical practice [(1)][1]. Since then, our
- Published
- 2019
14. ASSOCIATION BETWEEN ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITION, CARDIOVASCULAR BIOMARKERS AND CARDIAC REMODELING IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- Author
-
Kristin M Williamson, James L. Januzzi, Ritvik R Kandanelly, Alexander Camacho, Sean P. Murphy, Jonathan H Ward, Javed Butler, Scott D. Solomon, Ileana L. Piña, Alan S. Maisel, G. Michael Felker, and Margaret F. Prescott
- Subjects
medicine.medical_specialty ,Angiotensin receptor ,Ejection fraction ,business.industry ,Cardiovascular biomarkers ,Ventricular wall ,medicine.disease ,Sacubitril ,Valsartan ,Internal medicine ,Heart failure ,cardiovascular system ,Cardiology ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Neprilysin ,medicine.drug - Abstract
Background: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proB...
- Published
- 2021
15. Atrial Natriuretic Peptide Mediates Reverse Cardiac Remodeling During Treatment with Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction
- Author
-
Ileana L. Piña, James L. Januzzi, John C. Burnett, Alexander Camacho, Sean P. Murphy, Nasrien E. Ibrahim, Margaret F. Prescott, Javed Butler, Seethalakshmi R. Iyer, Scott D. Solomon, Cheryl A. Abbas, Alan S. Maisel, and G. Michael Felker
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,medicine.disease ,Sacubitril ,chemistry.chemical_compound ,Valsartan ,Atrial natriuretic peptide ,chemistry ,Heart failure ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Cyclic guanosine monophosphate ,Neprilysin ,hormones, hormone substitutes, and hormone antagonists ,Sacubitril, Valsartan ,circulatory and respiratory physiology ,medicine.drug - Abstract
Introduction Sacubitril/valsartan (S/V) promotes reverse cardiac remodeling in patients with HFrEF. Neprilysin inhibition results in increase of several vasoactive peptides that may mediate effects of S/V, however its effects on atrial natriuretic peptide (ANP) are largely unknown. Effects of ANP are mediated by cyclic guanosine monophosphate (cGMP). Hypothesis Longitudinal change in ANP concentration following initiation of S/V is associated with reverse cardiac remodeling. Methods Within a prospective open-label study of initiation and titration of S/V in patients with HFrEF, this pre-specified sub-study included patients in whom ANP was measured from samples collected in protease inhibitors to minimize its degradation. Concentrations of ANP and cGMP were measured at baseline and serially through 12 months of treatment. Echocardiographic assessment of LVEF and left atrial volume index (LAVi) was performed at baseline, 6 and 12 months. Results Among 144 participants (mean age 64.5 years; LVEF 30.8%), median ANP concentration at baseline was 102 pg/mL. Following initiation of S/V, ANP increased steeply and consistently during the first 2 months, with a significant increase in log-transformed ANP concentration at Day 14 (from 4.60 pg/mL to 5.05 pg/mL; Δ = 0.453; P Conclusions Concentrations of ANP increase substantially after initiation of S/V in patients with HFrEF. Larger early increases in ANP after S/V initiation were associated with greater magnitude of reverse cardiac remodeling (PROVE-HF; NCT02887183).
- Published
- 2020
16. CARDIAC REHABILITATION FOR TYPE 2 MYOCARDIAL INFARCTION
- Author
-
Muthiah Vaduganathan, Saad Rehman, Sean P. Murphy, Joshua Cohen, Cian P. McCarthy, David S. Olshan, Avinainder Singh, Maeve Jones-O'Connor, Jason H. Wasfy, and James L. Januzzi
- Subjects
Clinical Practice ,medicine.medical_specialty ,Rehabilitation ,business.industry ,Internal medicine ,medicine.medical_treatment ,Cardiology ,Medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease - Abstract
Patients with type 2 myocardial infarction (MI) related to supply-demand inequity are frequently encountered in clinical practice but, in the absence of evidence-based therapies, their prognosis remains poor; 5-year survival is less than 40%. Cardiac rehabilitation is associated with reduced all
- Published
- 2019
17. Quebec's Charter of Values: Preliminaries to the Charter - Implications of State Sovereignty Over Education, Religion and Ethics
- Author
-
Sean P. Murphy, J. Budziszewski, Shahid Athar, Abdulaziz Sachedina, and Roger Trigg
- Subjects
Politics ,Government ,Sovereignty ,State (polity) ,Political science ,Law ,media_common.quotation_subject ,Religious education ,Deference ,Charter ,Public administration ,Conscience ,media_common - Abstract
Summary This outline suggests that the principal political parties in Quebec are committed to the position thatthe state and its functionaries are the primary authorities in education, including the moral, ethicaland religious education of children. They appear to relegate parents and subsidiary institutions -especially religious authorities - to what is, at best, a secondary role: one, moreover, that can beunilaterally defined and limited - perhaps even abolished - by state power.There is no reason to believe that health care workers and their associations will be treateddifferently. It is very doubtful that the government would afford state functionaries a deference thatit denies to parents in the education of their own children.Return to the question: will the government of Quebec - sooner or later - use its Charter of Values tosuppress freedom of conscience and religion among health care workers?The Quebec government's assumption of sovereignty over education and the religious and ethical
- Published
- 2013
18. Conscientious Objection as a Crime Against Humanity
- Author
-
John Fleming, J. Budziszewski, Shahid Athar, Sean P. Murphy, and Janet Ajzenstat
- Subjects
Human rights ,Torture ,Conscientious objector ,media_common.quotation_subject ,Abortion ,Repeal ,humanities ,Political science ,Law ,Reproductive rights ,Health law ,Treaty ,health care economics and organizations ,media_common - Abstract
When the National Association for the Repeal of Abortion Laws opened its doors in the United States in 1969, the claim that abortion was a “right” was directed only at the repeal of laws against the procedure, so that women would be free to seek abortions and, as the Globe and Mail put it, so that physicians would be able “to perform their duties according to their conscience and their calling.” At that time, Canadians were repeatedly assured that “nobody would be forcing abortion procedures on anyone else.”Current rights claims must be distinguished from this early period. Contrary to early activist promises, current rights claims are meant to force health care workers and institutions to provide or at least facilitate abortion, contraception, and artificial reproduction, all of which remain morally controversial. A major “mover and shaker” in this project is the Center for Reproductive Rights (CRR), The ultimate goal of the CRR is to establish what it calls “hard norms” - treaty-based international laws - that recognize access to abortion as a fundamental human right. It plans to develop a “culture of enforcement” that will compel governments to respect this right and enforce it against physicians and other health care workers. Even as it works toward this end, it is cultivating “soft norms” in the form of statements by international, regional, and intergovernmental bodies.Canadian Professor Bernard M. Dickens appears to follow this strategy in a standard text, Canadian Health Law and Policy, in his chapter on Informed Consent, addressing the topic of conscientious objection and disclosure of relevant information to a patient. He very selectively borrows terms from the Treaty of Rome and arranges his material to make it appear that conscientious objection that delays access to the morning after pill or abortion is actually or very nearly a crime against humanity analogous to torture, or, at least, an egregious violation of human rights. He also leaves out everything necessary for a proper understanding of the Treaty of Rome, which, incidentally, includes everything that might cause a reader to question his claims. Professor Dickens’ polemic seamlessly weaves the agenda of the Center for Reproductive Rights into a standard Canadian reference work. There is no doubt that this is advantageous to the Center and its allies, but it brings into question the reliability of Canadian Health Law and Policy. Perhaps it is time for a third and more carefully revised edition of the book.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.